André Choulika, Ph.D.
Chief Executive Officer & Board Director
André Choulika, Ph.D., is one of the founders of Cellectis and served as Chief Executive Officer since the company's inception in 1999. He served as Chairman of the Board of Directors from 2011 to November 2020 and President of Calyxt from August 2010 to July 2020. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +). In June 2019, Dr. Choulika was appointed to the Board of Directors of the Institut Pasteur.
André Choulika was recently awarded Chevalier of the Légion d'Honneur in France.
Steve Doares, Ph.D.
Senior Vice President, US Manufacturing and Site Head
Steve Doares, Ph.D., joined Cellectis from Biogen in July 2020 as Senior Vice President, US Manufacturing and Site Head of the Raleigh, North Carolina manufacturing facility. Dr. Doares is responsible for the deployment of Cellectis’ proprietary state-of-the-art gene-editing cell manufacturing facility in Raleigh, for clinical and commercial supplies of the Cellectis’ current immuno-oncology UCART product candidates.
At Biogen, Dr. Doares was Vice President, Global Manufacturing Sciences, responsible for technology transfer into cGMP manufacturing of processes from clinical through commercialization stages for Biogen’s therapeutic product portfolio, both internally and externally. He provided scientific expertise for process troubleshooting and lifecycle improvements; process monitoring, advanced modeling, and PAT implementation; and technical and vendor management expertise for raw materials and SUS/disposables. Dr. Doares was also overseeing both drug substance (Active Pharmaceutical Ingredient) and drug product processes, for biologics and pharmaceuticals, and was with Biogen since 2010. Before that, he spent 15 years at Wyeth/Pfizer in glycoconjugate vaccine process development and technology transfer, clinical trials material drug substance production, and quality assurance supporting a vaccine drug substance plant. Dr. Doares holds a Ph.D. in Biochemistry from the University of Georgia.
Philippe Duchateau, Ph.D.
Chief Scientific Officer
Philippe Duchateau, Ph.D., joined Cellectis in 2001 to pioneer the field of gene editing and has served as Chief Scientific Officer since 2012. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur (Lille, France), he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco, within the Cardiovascular Research Institute. Dr. Duchateau has led Cellectis’ Research department since 2004.
Mark Frattini, MD, PhD
Chief Medical Officer
In September 2022, Mark Frattini, M.D., Ph.D., was appointed Cellectis' Chief Medical Officer.
Dr. Frattini has over 20 years of experience in the field of hematological malignancies and joined Cellectis in August 2020 as Senior Vice President of Clinical Sciences where he has been responsible for Cellectis’ clinical leadership including the clinical development strategy of the Company’s current immune-oncology UCART product candidates. He has also been serving as a core member of the senior clinical team. As Chief Medical Officer, Dr. Frattini oversees clinical research and development for Cellectis’ UCART clinical trial programs.
Prior to joining Cellectis, Dr. Frattini was Executive Medical Director, Program Lead, Global Clinical Research & Development at Celgene/Bristol Myer Squibb and was responsible for the oversight and management of several of Celgene’s sponsored programs in the hematology therapeutic area. Before joining Celgene, Dr. Frattini spent over 16 years as a physician-scientist specializing in hematologic malignancies in academia at Memorial Sloan-Kettering Cancer Center and Columbia University where he was a member of the adult leukemia service and the Experimental Therapeutics center at both institutions. At Columbia University from 2013-2018 Mark also served as the Director of Research for Hematologic Malignancies.
Dr. Frattini holds a M.D. and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago and received his Internal Medicine residency and Medical Oncology fellowship training at Johns Hopkins Hospital.
Executive Vice President, Chief Human Resources Officer
Kyung Nam-Wortman joined Cellectis in November 2020 as Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman’s role is to ensure that the Company advances its roadmap through the recruitment and retention of top talent. She also works to further develop and enhance Cellectis’ dynamic and inclusive culture, while optimizing the Company’s human resources function.
Kyung Nam-Wortman joined Cellectis from Achillion (recently acquired by Alexion in January 2020) where she served as Senior Vice President, Head of Human Resources, Head of Information Technology, Facilities and Internal Communications. At Achillion, she was responsible for leading the strategic and operational components of the aforementioned functions.
Prior to her tenure at Achillion, Ms. Nam-Wortman served as Vice President and Head of Global Talent and Organization Capability at Zoetis, where she supported the spin-off of Pfizer’s animal health business unit through its IPO and was responsible for the stand up of Zoetis’ global talent management function to support the company’s growth worldwide. She also held various human resource leadership roles for Pfizer’s business units, divisions, and functions with regional and global accountabilities.
In addition to her experience in biotech/biopharma, Ms. Nam-Wortman has 14 years of experience in the consulting industry focused on strategic and organization change management from Delta Consulting Group and IBM. She received her bachelor’s in marketing from New York University Stern School of Business and MS in human resources management / organization development from the New School of Social Research.
Chief Regulatory and Compliance Officer
Stephan Reynier, MSc, joined Cellectis in April 2011. He serves as Chief Regulatory and Compliance Officer after holding the position of Head of Programs at Ectycell, a former subsidiary of Cellectis, from April 2011 to 2014 with the mission of managing and coordinating internal and external collaborative programs. As Chief Regulatory and Compliance Officer, Mr. Reynier is in charge of ensuring a speedy and successful development of the UCART product family by establishing close interactions with regulatory agencies such as EMA and FDA, while securing compliance to applicable regulations, regulatory guidelines and quality assurance standards. Mr Reynier has extensive experience, from his previous positions as Senior Director at Voisin Consulting Life Sciences and European Associate Director Medical Affairs at Gilead Sciences, in the design and implementation of regulatory strategies for the development of drugs and biologics, with a strong focus on cell and gene therapy.
Mr Reynier graduated as Agro-Engineer in France and received a Master of Science in Chemical Engineering from the University of Toronto, Canada.
David Sourdive, Ph.D.
Executive Vice President CMC and Manufacturing
David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016 and as Executive Vice President, Technical Operations until July, 2019. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.
Chief Business Officer
Arthur Stril serves as Cellectis’ Chief Business Officer since September 2020, overseeing business development, strategy, and program management. Arthur joined Cellectis in July 2018 as Vice President, Corporate Development. Arthur began his career at the European Commission’s Directorate-General for Competition, controlling global pharmaceutical mergers such as the Novartis/GSK and Sanofi/Boehringer Ingelheim asset swaps, Pfizer’s acquisition of Hospira, and Teva’s acquisition of Actavis Generics. He later became Head of the Hospital Financing unit at the French Ministry of Health, where he led a team responsible for the €80bn hospital budget. Arthur graduated from the École Normale Supérieure, Paris & Cambridge University, and holds a diploma in Immunotherapy from the Université Paris-Descartes. Arthur is also a member of the French Corps des Mines.
Marie-Bleuenn Terrier joined Cellectis as Legal Counsel in 2008, and was appointed General Counsel in 2013. Prior to joining Cellectis, she worked as Legal Counsel for Pfizer from 2004 to 2006, and for Boehringer Ingelheim from 2006 to 2008. Marie-Bleuenn Terrier has served as Secretary of the Board of Directors of Cellectis since 2015. She holds a Master’s degree in Law from the Panthéon La Sorbonne University in Paris.
Bing Wang, PhD, MBA
Chief Financial Officer
Dr. Wang is a highly accomplished biotechnology executive who brings extensive global finance experience in the biotechnology industry including a background with global public companies in corporate finance, mergers and acquisitions, operations management systems, and financial planning and analysis. He joins Cellectis to oversee the company’s global finance team reporting directly to Chief Executive Officer, André Choulika, PhD. \
Prior to joining Cellectis, Dr. Wang was most recently the Chief Executive Officer and Director of Refuge Biotechnologies Inc., a cell therapy immune-oncology biotechnology company leveraging synthetic biology and gene engineering, which he co-founded following nearly a decade of healthcare investment banking experience. Prior to his tenure at Refuge, Dr. Wang worked in healthcare investment banking at Barclays Capital Inc. and Citigroup Global Markets Inc.
At Barclay’s, Dr. Wang served as director of healthcare investment banking where he acted as strategic financial advisor and helped raised capital for companies in the healthcare industry. Dr. Wang had also served as Board Director at KBP Biosciences, a clinical-stage biotechnology company. He is currently on the advisory board of the Healthcare and Pharmaceutical Management Program at Columbia Business School.
Dr. Wang holds a Bachelor of Science in Applied Physics from Columbia University, MA and Ph.D. in Electrical Engineering from Princeton University, and MBA from Columbia Business School.
Jean-Pierre Garnier, Ph.D.
Chairman of the Board of Directors
Jean-Pierre Garnier, Ph.D., was appointed non-executive Chairman of the board in November 2020. Dr. Garnier is a seasoned leader with decades of experience within the global bio-pharma industry.
Most recently, Dr. Garnier was Chairman of Idorsia, a public bio-technology company based in Switzerland and listed on the Swiss Stock Exchange (SIX), which was spun off of Actelion LTD with a billion-dollar investment from Johnson & Johnson (J&J). Previous to his tenure at Idorsia, he was Chairman of Actelion Ltd., a Swiss pharmaceuticals and bio-technology company. In 2017, Actelion LTD was sold for $30 billion to J&J.
Dr. Garnier previously served as Chief Executive Officer of Pierre Fabre SA (2008 to 2010), as Chief Executive Officer and Executive Member of the Board of Directors of GlaxoSmithKline plc (2000 to 2008), and as Chief Executive Officer of SmithKline Beecham plc (2000). Before becoming CEO at SmithKline Beecham plc, he served as Chief Operating Officer and Executive Member of the Board of Directors from 1996 to 2000.
Dr. Garnier has been a Board member of Renault S.A. (2008 to 2016), United Technologies Corporation (1997 to 2019), and Max Planck Institute (2013 to 2019).
Since 2018, he has served Chairman of the Board of Directors of Carmat, a public (Euronext Paris) artificial heart company based in France. Since 2015, Dr. Garnier has served as Director of the board of Radius Therapeutics, a Nasdaq-listed pharmaceutical company and, since 2019, as Lead Director of the board of directors of Carrier Global Corp., a NYSE-listed HVAC, refrigeration, fire and security solutions company. He is currently a member of the Paul Newman Own Advisor Board.
In 2006, Dr. Garnier was named as one of the top 20 Worldwide CEOs by the Best Practice Institute. He was made a Knight Commander of the British Empire. Finally, he was most recently promoted from Chevalier to Officier de la Légion d’Honneur of France.
Dr. Garnier holds an MS in pharmaceutical science and a Ph.D. in pharmacology from the Louis Pasteur University of Strasbourg, France. He subsequently earned his MBA at Stanford University, California, as a Fulbright Scholar.
Laurent Arthaud has served as a member of Cellectis’ Board of Directors since 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement (formerly CDC Enterprises, a subsidiary of Caisse des Dépôts) since 2012. From 2006 to 2012, Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Mr. Arthaud is a graduate of the École Polytechnique and the l’École Nationale de Statistique et d’Administration Économique.
* Independent Director according to Nasdaq rules
Pierre Bastid has served as a member of Cellectis’ Board of Directors since 2011. Mr. Bastid has 25 years experience in turning around, developing and running technology businesses in Asia, Europe and the U.S. In particular, he initiated and completed the most successful European management buy out of the last 15 years: he bought the Power Conversion Division of French Engineering Alstom for $100M in 2005 and sold it to General Electric in 2011 for $3B.
In addition to his involvement with Cellectis, Mr. Bastid is currently a large shareholder, serving on the Board for Pharnext (another very innovative biotech company), Hougou (his own investment company), ZAKA and GRID (his own Paris based and New-York based real estate companies), Shango (his own Private Equity company), EVOK (his own hotel group), Nepteam (a shipbuilding company). Mr. Bastid also advises a number of Investment and Private Equity firms. Pierre is a trustee of Juilliard School of Music and other non-profit organizations based in the U.S.
*Independent Director according to Nasdaq rules
Donald A. Bergstrom, M.D., Ph.D
Cellectis announced on June 28, 2022 the appointment of Donald A Bergstrom, M.D., Ph.D., as a Director on the Company’s Board of Directors. Dr. Bergstrom, currently serves as Executive Vice President, Head of Research and Development at Relay Therapeutics, Inc., a clinical-stage precision medicines company. He brings with him over 15 years of experience in the biopharmaceutical and medical industries.
Prior to his tenure at Relay Therapeutics, Dr. Bergstrom was Chief Medical Officer at Mersana Therapeutics, where he led the advancement of two products based on Mersana’s proprietary antibody-drug conjugate platform through non-clinical development and into Phase 1 clinical trials. Prior to Mersana, he was Global Head of Translational and Experimental Medicine at Sanofi Oncology. At Sanofi, Dr. Bergstrom held roles of increasing responsibility at Merck Research Laboratories, culminating in his role as Oncology Franchise Lead, Experimental Medicine. Dr. Bergstrom was also recently appointed to the Board of Directors at Fusion Pharmaceuticals.
Dr. Bergstrom holds an M.D. from the University of Washington, Seattle, and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed his post-doctoral training. He was a resident in clinical pathology at the University of Washington.
Rainer Boehm, MD
Rainer Boehm spent 29 years at Novartis, working locally, regionally and globally in various Senior Management roles, after building his career in Marketing & Sales and Medical Affairs. He led all emerging markets regions as well as the United States and Canada, either for Oncology or the Pharmaceuticals division. His most recent assignments were Chief Commercial and Medical Affairs Officer globally for Novartis Pharma, as well as ad interim CEO and Division Head Pharma. Rainer launched and oversaw the commercialization of many brands during his career, amongst them Femara, Zometa and Glivec, as well as Cosentyx and Entresto. His broad interests include leadership development, coaching and mentoring, access to medicines and new business models including solutions to leverage digital medicines and real world evidence. Rainer has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.
Mr. Godard has served as a member of Cellectis’ Board of Directors since 2007. He is a graduate of the Ecole Nationale Supérieure Agronomique de Toulouse and began his agronomy career in 1967 in Africa as a researcher at the Institut de Recherche pour les Huiles et Oléagineux. He joined the French chemical group Rhône-Poulenc in 1975 where he got various management positions in France and abroad before becoming CEO of the agrochemical subsidiary in 1991. In 1999 he was directly involved in the merger of Rhône-Poulenc and Hoechst to create Aventis and was appointed CEO of the Aventis CropScience subsidiary with a significant involvement in seeds and ag biotechnology. He left Aventis in 2002 to create a consulting company specialized in agriculture and biotechnology.
Hervé Hoppenot joined Incyte Corporation in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Incyte is one of the fastest growing biopharmaceutical companies in the U.S. Incyte’s team of more than 1,000 scientists, clinicians, and other team members operating in 15 countries, strives to discover and develop first-in-class and best-in-class medicines for cancer and other diseases. The Company is advancing a diverse portfolio of large and small molecules comprised of 18 development candidates against 14 different molecular targets and in 2016 Incyte reported revenue of more than $1 billion.
Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, which included $11 billion in global sales, the largest oncology pipeline in the industry and 8000 employees in 50 countries. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. He and his family are dual citizens of France and the United States, having moved to the U.S. in 1991.
Axel-Sven Malkomes served as Chief Financial Officer & Chief Business Officer at Medigene AG, a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, until March 31st, 2022. He brings with him over 25 years of experience in the healthcare sector.
Previous to his tenure at Medigene, Mr. Malkomes served as Vice Chairman & Managing Director of the Life Sciences Practice for the British bank Barclays in Europe. Prior to joining Barclays, he was Global Head of Healthcare & Chemicals Investment Banking at the French corporate and investment bank Société Générale.
On the investor side, Mr. Malkomes has accumulated relevant experience during his several years with the UK listed private equity firm 3i plc. as co-head of European Healthcare Investments. Previously, he had leading operational and corporate roles at the German pharmaceutical company Merck KGaA, i.e. as Head of Strategic Planning as well as Head of Mergers & Acquisitions/Business Development, where he significantly participated in the initial set-up and build-out of the company's oncology business.
During his international management career, Mr. Malkomes gained extensive knowledge of the pharmaceutical industry.
Annick Schwebig, MD
Annick Schwebig, MD, has served as a member of Cellectis’ Board of Directors since 2011. In 2000, she founded the French subsidiary of Actelion, of which she is the General Manager. Actelion is a biopharmaceuticals company specializing in innovative treatments to serve unmet medical needs. A graduate of the University of Paris medical school, Dr. Schwebig worked as a senior manager at the biopharmaceuticals company Bristol-Myers Squibb for 17 years from 1983 to 2000.
Prof. Catherine Bollard
Director, Center for Cancer and Immunology Research, Children’s Research Institute, Children's National Health System and Professor of Pediatrics and Immunology, The George Washington University, Washington DC
Professor Catherine Bollard, MBChB, MD, FRACP, FRCPA, is Director of the Center for Cancer and Immunology Research and Director of the Program for Cell Enhancements and Technologies for Immunotherapy at the Children’s Research Institute, Children’s National Health System and The George Washington University. A distinguished hematologist and immunotherapist, Dr. Bollard’s research interests focus on areas that include developing cell and gene therapies for patients with cancer and underlying immune deficiencies.
Dr. Stephan Grupp
Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia
Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia (CHOP), and the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania. A bone marrow transplant physician, he is a member of the Division of Oncology and the Medical Director of the Cell and Gene Therapy Lab. Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date, as well as the global registration trial for CTL019. As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 180 peer-reviewed journal articles, as well as numerous abstracts and book chapters.
Prof. Ola Landgren
Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, New York, NY
Professor Ola Landgren, MD, is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center New York and Professor of Medicine at Weill Cornell Medical College. He is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring. He has a strong interest in the development of early-treatment clinical trials, targeting high-risk smoldering myeloma. He develops new strategies (including cell-based, molecular-based and imaging-based) and implements advanced MRD testing in clinical trials at MSK.
Dr. Marcela Maus
Director of Cellular Immunotherapy at the Massachusetts General Hospital, Boston, MA
Doctor Marcela V. Maus, MD, PhD, is Director of Cellular Immunotherapy at the Massachusetts General Hospital in Boston and Assistant Professor at Harvard Medical School. She is a board-certified hematologist-oncologist with extensive research experience in all aspects of pre-clinical and clinical design and use of cell therapies and gene-modified T-cells for cancer. Dr Maus completed undergraduate studies at MIT and her MD and PhD at Penn. As a graduate student, she worked with Dr. Carl June on the biology of human T cell activation. She completed residency training in internal medicine at the University of Pennsylvania Health System, and completed fellowship training in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center. Her research focuses on the pre-clinical development and clinical translation of engineered T cell therapies.
Prof. Ghulam J. Mufti
Professor of Hemato-oncology and Head of Department, King's College Hospital, Department of Hematological Medicine, London, UK
Professor Ghulam J Mufti is one of the founding members of The MDS Foundation Inc. He is also the head of the department of hematological medicine at Guy’s, King’s and St Thomas’s hospitals, King’s College London, with a team of 13 professors, 6 senior lecturers/lecturers and approximately 100+ research staff. In addition, Professor Mufti is a non-executive director of King’s College Hospital NHS Foundation Trust and was awarded an Officer of the Order of British Empire (OBE) in the Queen’s New Year honors list in January 2017.
Professor Ghulam Mufti has extensive clinical and research expertise in leukemias, lymphomas and in particular myelodysplastic syndromes, for which he is internationally renowned. His particular area of research has focused on molecular aberrations in MDS/AML and the identification of novel therapies that include gene and cell based therapies. He has published 500+ papers (H-Index: 78, I-Index: 11) and chapters in scientific journals and textbooks on leukemias /MDS and bone marrow failure syndromes.
Prof. Dietger Niederwieser
Professor of Medicine, Head of the Division of Hematology and Medical Oncology at the University of Leipzig, Germany
Professor Dietger Niederwieser, MD, is Professor of Medicine, Head of the Division of Hematology and Medical Oncology at University of Leipzig and University Hospital. His therapeutic areas of expertise include Clinical Immunology, Hematology and Oncology, and his research is focused on stem cell transplantation, cell therapies and gene therapies. He has extensive experience in health economics, outcomes research, clinical development of innovative drugs and clinical studies.
Prof. Kanti Rai
Professor of Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, Hempstead, USA
Professor Rai, an internationally renowned leukemia researcher and hematologist, brings extensive knowledge and experience from his 50-year career spanning groundbreaking clinical leukemia research. He is the Joel Finkelstein Cancer Foundation Professor of Medicine at the Hofstra North Shore-LIJ School of Medicine, where he is also Professor of Molecular Medicine. He is currently Chief of the Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program at Northwell Cancer Institute and an Investigator at The Feinstein Institute for Medical Research.